WO2008084472A2 - Improved process for the preparation of oxidized phospholipids - Google Patents
Improved process for the preparation of oxidized phospholipids Download PDFInfo
- Publication number
- WO2008084472A2 WO2008084472A2 PCT/IL2008/000013 IL2008000013W WO2008084472A2 WO 2008084472 A2 WO2008084472 A2 WO 2008084472A2 IL 2008000013 W IL2008000013 W IL 2008000013W WO 2008084472 A2 WO2008084472 A2 WO 2008084472A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- group
- glycerolic backbone
- moiety
- reacting
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 179
- 150000003904 phospholipids Chemical class 0.000 title abstract description 67
- 238000002360 preparation method Methods 0.000 title abstract description 38
- 230000008569 process Effects 0.000 title description 35
- 150000001875 compounds Chemical class 0.000 claims abstract description 586
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 claims abstract description 102
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims abstract description 32
- 238000004440 column chromatography Methods 0.000 claims abstract description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 126
- 239000002904 solvent Substances 0.000 claims description 105
- 239000000203 mixture Substances 0.000 claims description 73
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 62
- 239000007800 oxidant agent Substances 0.000 claims description 58
- -1 phosphatidyl cardiolipin Chemical group 0.000 claims description 58
- 239000011541 reaction mixture Substances 0.000 claims description 50
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 45
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 45
- 125000000217 alkyl group Chemical group 0.000 claims description 39
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 36
- 125000006239 protecting group Chemical group 0.000 claims description 36
- 125000004432 carbon atom Chemical group C* 0.000 claims description 34
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 33
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical group NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 claims description 32
- 150000002009 diols Chemical class 0.000 claims description 32
- 229910052739 hydrogen Inorganic materials 0.000 claims description 28
- 125000003118 aryl group Chemical group 0.000 claims description 27
- 239000012074 organic phase Substances 0.000 claims description 27
- 230000001590 oxidative effect Effects 0.000 claims description 25
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 claims description 25
- 239000001257 hydrogen Substances 0.000 claims description 24
- 239000012535 impurity Substances 0.000 claims description 24
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 claims description 21
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 20
- 229910019142 PO4 Inorganic materials 0.000 claims description 18
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 18
- 235000011180 diphosphates Nutrition 0.000 claims description 17
- 150000002118 epoxides Chemical class 0.000 claims description 17
- 239000010452 phosphate Substances 0.000 claims description 17
- 229950004354 phosphorylcholine Drugs 0.000 claims description 17
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 16
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 16
- GIELSVRJHGSIJE-UHFFFAOYSA-N (oxo-lambda5-phosphanylidyne)methanol Chemical group P(=O)#CO GIELSVRJHGSIJE-UHFFFAOYSA-N 0.000 claims description 15
- QQHVEZXEGWKJEP-UHFFFAOYSA-N 2-(oxo-lambda5-phosphanylidyne)ethanol Chemical group OCC#P=O QQHVEZXEGWKJEP-UHFFFAOYSA-N 0.000 claims description 15
- VDRKXDRYHWOORA-UHFFFAOYSA-N 4-(oxo-$l^{5}-phosphanylidyne)butan-1-ol Chemical group OCCCC#P=O VDRKXDRYHWOORA-UHFFFAOYSA-N 0.000 claims description 15
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 15
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoserine Chemical group OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 claims description 15
- VZYZHAVHYMUSNJ-UHFFFAOYSA-N [2-(dinitroamino)-1-phenylethyl] dihydrogen phosphate Chemical compound [N+](=O)([O-])N(CC(OP(=O)(O)O)C1=CC=CC=C1)[N+](=O)[O-] VZYZHAVHYMUSNJ-UHFFFAOYSA-N 0.000 claims description 15
- 150000002148 esters Chemical class 0.000 claims description 15
- JGENYNHRIOHZOP-UHFFFAOYSA-N ethyl 2-(trimethylazaniumyl)ethyl phosphate Chemical group CCOP([O-])(=O)OCC[N+](C)(C)C JGENYNHRIOHZOP-UHFFFAOYSA-N 0.000 claims description 15
- 229960000367 inositol Drugs 0.000 claims description 15
- 239000008101 lactose Substances 0.000 claims description 15
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 15
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 15
- OKLITDBMRKBZLC-UHFFFAOYSA-N 3-(oxo-$l^{5}-phosphanylidyne)propan-1-ol Chemical group OCCC#P=O OKLITDBMRKBZLC-UHFFFAOYSA-N 0.000 claims description 14
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 14
- 150000004820 halides Chemical group 0.000 claims description 13
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 13
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical group CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 12
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Chemical group NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 12
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Chemical group OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 12
- 150000008104 phosphatidylethanolamines Chemical group 0.000 claims description 12
- 150000003905 phosphatidylinositols Chemical group 0.000 claims description 12
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 11
- 150000002978 peroxides Chemical class 0.000 claims description 11
- 239000008346 aqueous phase Substances 0.000 claims description 10
- 229910001919 chlorite Inorganic materials 0.000 claims description 10
- 229910052619 chlorite group Inorganic materials 0.000 claims description 10
- QBWCMBCROVPCKQ-UHFFFAOYSA-N chlorous acid Chemical compound OCl=O QBWCMBCROVPCKQ-UHFFFAOYSA-N 0.000 claims description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 10
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 9
- 150000001241 acetals Chemical class 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 7
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 6
- 125000000524 functional group Chemical group 0.000 claims description 6
- 125000005547 pivalate group Chemical group 0.000 claims description 6
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 claims description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 5
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 claims description 5
- 150000001266 acyl halides Chemical class 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 230000002051 biphasic effect Effects 0.000 claims description 5
- 235000019253 formic acid Nutrition 0.000 claims description 5
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 claims description 5
- 229910000489 osmium tetroxide Inorganic materials 0.000 claims description 4
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 3
- 239000012280 lithium aluminium hydride Substances 0.000 claims description 3
- 229910001923 silver oxide Inorganic materials 0.000 claims description 3
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 claims description 3
- 239000012312 sodium hydride Substances 0.000 claims description 3
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 claims description 2
- 150000001735 carboxylic acids Chemical class 0.000 claims 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 9
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 6
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical group C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 claims 6
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 2
- 239000000543 intermediate Substances 0.000 abstract description 25
- 230000009286 beneficial effect Effects 0.000 abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 99
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 91
- 239000000243 solution Substances 0.000 description 77
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 76
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 75
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 64
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 56
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 38
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 38
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 31
- 150000001299 aldehydes Chemical class 0.000 description 30
- 238000006243 chemical reaction Methods 0.000 description 28
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 25
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 24
- 239000000047 product Substances 0.000 description 22
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 20
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
- 238000001914 filtration Methods 0.000 description 18
- 238000007254 oxidation reaction Methods 0.000 description 18
- 150000002632 lipids Chemical class 0.000 description 17
- 150000002313 glycerolipids Chemical class 0.000 description 16
- 230000003647 oxidation Effects 0.000 description 15
- 239000007832 Na2SO4 Substances 0.000 description 14
- 229910052938 sodium sulfate Inorganic materials 0.000 description 14
- YHHSONZFOIEMCP-UHFFFAOYSA-N 2-(trimethylazaniumyl)ethyl hydrogen phosphate Chemical compound C[N+](C)(C)CCOP(O)([O-])=O YHHSONZFOIEMCP-UHFFFAOYSA-N 0.000 description 13
- 229960004592 isopropanol Drugs 0.000 description 13
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- 239000012043 crude product Substances 0.000 description 12
- 150000002431 hydrogen Chemical group 0.000 description 12
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 12
- 235000017557 sodium bicarbonate Nutrition 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 239000000741 silica gel Substances 0.000 description 11
- 229910002027 silica gel Inorganic materials 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 125000002947 alkylene group Chemical group 0.000 description 10
- 150000002327 glycerophospholipids Chemical class 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 235000019439 ethyl acetate Nutrition 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical group [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 201000001320 Atherosclerosis Diseases 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 125000004103 aminoalkyl group Chemical group 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000006227 byproduct Substances 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 238000010533 azeotropic distillation Methods 0.000 description 5
- 125000000753 cycloalkyl group Chemical group 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 231100001261 hazardous Toxicity 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 238000007040 multi-step synthesis reaction Methods 0.000 description 5
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 5
- 239000012286 potassium permanganate Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 238000007248 oxidative elimination reaction Methods 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 4
- OOWQBDFWEXAXPB-IBGZPJMESA-N 1-O-hexadecyl-sn-glycerol Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](O)CO OOWQBDFWEXAXPB-IBGZPJMESA-N 0.000 description 3
- YSULOORXQBDPCU-UHFFFAOYSA-N 2-(trimethylazaniumyl)ethanehydrazonate;hydrochloride Chemical group [Cl-].C[N+](C)(C)CC(=O)NN YSULOORXQBDPCU-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- SCKXCAADGDQQCS-UHFFFAOYSA-N Performic acid Chemical compound OOC=O SCKXCAADGDQQCS-UHFFFAOYSA-N 0.000 description 3
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 3
- 235000019799 monosodium phosphate Nutrition 0.000 description 3
- 239000012454 non-polar solvent Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- RKIDALSACBQVTN-HHHXNRCGSA-N 1-O-palmitoyl-2-O-(5-oxovaleryl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCC=O)COP([O-])(=O)OCC[N+](C)(C)C RKIDALSACBQVTN-HHHXNRCGSA-N 0.000 description 2
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 2
- HNTGIJLWHDPAFN-UHFFFAOYSA-N 1-bromohexadecane Chemical compound CCCCCCCCCCCCCCCCBr HNTGIJLWHDPAFN-UHFFFAOYSA-N 0.000 description 2
- NGXQYIUTTZZUHT-UHFFFAOYSA-N 3-hexadecylperoxypropane-1,2-diol Chemical compound CCCCCCCCCCCCCCCCOOCC(O)CO NGXQYIUTTZZUHT-UHFFFAOYSA-N 0.000 description 2
- RIMXEJYJXDBLIE-UHFFFAOYSA-N 6-bromohex-1-ene Chemical compound BrCCCCC=C RIMXEJYJXDBLIE-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 239000012670 alkaline solution Substances 0.000 description 2
- 230000036523 atherogenesis Effects 0.000 description 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 2
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 2
- 229910001863 barium hydroxide Inorganic materials 0.000 description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- 239000000920 calcium hydroxide Substances 0.000 description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 150000001805 chlorine compounds Chemical group 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000010549 co-Evaporation Methods 0.000 description 2
- 229910000365 copper sulfate Inorganic materials 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 125000005429 oxyalkyl group Chemical group 0.000 description 2
- 238000005949 ozonolysis reaction Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 230000010118 platelet activation Effects 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 2
- 229960002218 sodium chlorite Drugs 0.000 description 2
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- LZTRCELOJRDYMQ-UHFFFAOYSA-N triphenylmethanol Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(O)C1=CC=CC=C1 LZTRCELOJRDYMQ-UHFFFAOYSA-N 0.000 description 2
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 2
- 229940045860 white wax Drugs 0.000 description 2
- MLIWQXBKMZNZNF-KUHOPJCQSA-N (2e)-2,6-bis[(4-azidophenyl)methylidene]-4-methylcyclohexan-1-one Chemical compound O=C1\C(=C\C=2C=CC(=CC=2)N=[N+]=[N-])CC(C)CC1=CC1=CC=C(N=[N+]=[N-])C=C1 MLIWQXBKMZNZNF-KUHOPJCQSA-N 0.000 description 1
- 0 *OCC(CON)OCCCCC=C Chemical compound *OCC(CON)OCCCCC=C 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- FKASAVXZZLJTNX-UHFFFAOYSA-N 2-(dimethylamino)acetic acid;hydrochloride Chemical group [Cl-].C[NH+](C)CC(O)=O FKASAVXZZLJTNX-UHFFFAOYSA-N 0.000 description 1
- YNJSNEKCXVFDKW-UHFFFAOYSA-N 3-(5-amino-1h-indol-3-yl)-2-azaniumylpropanoate Chemical compound C1=C(N)C=C2C(CC(N)C(O)=O)=CNC2=C1 YNJSNEKCXVFDKW-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- MOQVHOPVBREXLY-UHFFFAOYSA-N 3h-dioxol-4-ylmethanol Chemical compound OCC1=COOC1 MOQVHOPVBREXLY-UHFFFAOYSA-N 0.000 description 1
- STABAPSYCQFWOK-UHFFFAOYSA-N 4-chlorobenzenecarboperoxoic acid Chemical compound OOC(=O)C1=CC=C(Cl)C=C1 STABAPSYCQFWOK-UHFFFAOYSA-N 0.000 description 1
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- CVEUMFIXNQKMJF-KWCCSABGSA-N CCCCCCC(C[N+](C)(C)C)OP([O-])(OC[C@@H](CO)O)=O Chemical compound CCCCCCC(C[N+](C)(C)C)OP([O-])(OC[C@@H](CO)O)=O CVEUMFIXNQKMJF-KWCCSABGSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- 229910004879 Na2S2O5 Inorganic materials 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- RNVYQYLELCKWAN-RXMQYKEDSA-N [(4r)-2,2-dimethyl-1,3-dioxolan-4-yl]methanol Chemical compound CC1(C)OC[C@@H](CO)O1 RNVYQYLELCKWAN-RXMQYKEDSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 150000001649 bromium compounds Chemical group 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- CHVJITGCYZJHLR-UHFFFAOYSA-N cyclohepta-1,3,5-triene Chemical compound C1C=CC=CC=C1 CHVJITGCYZJHLR-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- WVPKAWVFTPWPDB-UHFFFAOYSA-N dichlorophosphinic acid Chemical group OP(Cl)(Cl)=O WVPKAWVFTPWPDB-UHFFFAOYSA-N 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- AFRWBGJRWRHQOV-UHFFFAOYSA-N ethyl 5-bromopentanoate Chemical compound CCOC(=O)CCCCBr AFRWBGJRWRHQOV-UHFFFAOYSA-N 0.000 description 1
- OOBFNDGMAGSNKA-UHFFFAOYSA-N ethyl 7-bromoheptanoate Chemical compound CCOC(=O)CCCCCCBr OOBFNDGMAGSNKA-UHFFFAOYSA-N 0.000 description 1
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
- 229910001448 ferrous ion Inorganic materials 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N linoleic acid group Chemical group C(CCCCCCC\C=C/C\C=C/CCCCC)(=O)O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- VUQUOGPMUUJORT-UHFFFAOYSA-N methyl 4-methylbenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C(C)C=C1 VUQUOGPMUUJORT-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002825 nitriles Chemical group 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 238000010915 one-step procedure Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- MPQXHAGKBWFSNV-UHFFFAOYSA-N oxidophosphanium Chemical class [PH3]=O MPQXHAGKBWFSNV-UHFFFAOYSA-N 0.000 description 1
- AUONHKJOIZSQGR-UHFFFAOYSA-N oxophosphane Chemical compound P=O AUONHKJOIZSQGR-UHFFFAOYSA-N 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 150000003003 phosphines Chemical class 0.000 description 1
- 125000005328 phosphinyl group Chemical group [PH2](=O)* 0.000 description 1
- AQSJGOWTSHOLKH-UHFFFAOYSA-N phosphite(3-) Chemical class [O-]P([O-])[O-] AQSJGOWTSHOLKH-UHFFFAOYSA-N 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000010963 scalable process Methods 0.000 description 1
- 150000003349 semicarbazides Chemical class 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
- C07F9/106—Adducts, complexes, salts of phosphatides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B41/00—Formation or introduction of functional groups containing oxygen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
- C07C29/48—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by oxidation reactions with formation of hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
- C07C41/01—Preparation of ethers
- C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
- C07C41/26—Preparation of ethers by reactions not forming ether-oxygen bonds by introduction of hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
- C07C45/29—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/16—Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/16—Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation
- C07C51/29—Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation with halogen-containing compounds which may be formed in situ
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/08—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/28—Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/39—Preparation of carboxylic acid esters by oxidation of groups which are precursors for the acid moiety of the ester
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to the field of synthetic chemistry, and more particularly, to novel synthetic processes useful for the preparation of oxidized phospholipids, derivatives, analogs and salts thereof.
- modified phospholipids are known in many applications.
- U.S. Patent No. 5,985,292 compositions for trans-dermal and trans- membranal application incorporating phospholipids bearing lipid-soluble active compounds are disclosed.
- U.S. Patent Nos. 6,261,597, 6,017,513 and 4,614,796 phospholipid derivatives incorporated into liposomes and biovectors for drug delivery are disclosed.
- U.S. Patent No. 5,660,855 lipid constructs of aminomannose- derivatized cholesterol suitable for targeting smooth muscle cells or tissue, formulated in liposomes, are disclosed. These formulations are aimed at reducing restenosis in arteries, using PTCA procedures.
- liposomes for treating atherosclerosis has been further disclosed in the PCT patent application published as WO 95/23592.
- pharmaceutical compositions of unilamellar liposomes that may contain phospholipids.
- the liposomes disclosed in WO 95/23592 are aimed at optimizing cholesterol efflux from atherosclerotic plaque and are typically non-oxidized phospholipids.
- Modified phospholipid derivatives mimicking platelet activation factor (PAF) structures are known to be pharmaceutically active, affecting such functions as vascular permeability, blood pressure and heart function inhibition.
- PAF platelet activation factor
- Oxidation of phospholipids occurs in vivo through the action of free radicals and enzymatic reactions abundant in atheromatous plaque.
- preparation of oxidized phospholipids usually involves simple chemical oxidation of a native LDL or LDL phospholipid component.
- Investigators studying the role of oxidized LDL have employed, for example, ferrous ions and ascorbic acid (Itabe, H., et al., J.Biol. Chem. 1996; 271:33208-217) and copper sulfate (George, J. et al., Atherosclerosis. 1998; 138:147-152; Ameli, S.
- oxidation techniques described above for preparing oxidized phospholipids involve reactions that are non-specific and yield a mixture of oxidized products.
- the non-specificity of the reactions reduces yield, requires a further separation step and raises concern for undesired side effects when the products are integrated in pharmaceutical compositions.
- Palmitoyl-2-(5-oxovaleroyl)-5n-glycero-3-phosphocholine (POVPC) and derivatives thereof such as l-palmitoyl-2-glutaroyl-5 «-glycero-3-phosphocholine (PGPC) are representative examples of mildly oxidized esterified phospholipids that have been studied with respect to atherogenesis (see, for example, Boullier et al., J. Biol. Chem.. 2000, 275:9163; Subbanagounder et al., Circulation Research, 1999, pp. 311).
- POVPC is typically prepared by providing a phosphatidyl choline bearing an unsaturated fatty acid and oxidizing the unsaturated bond of the fatty acid by, e.g., ozonolysis (oxidative cleavage) or using a periodate as an oxidizing agent.
- ozonolysis oxidative cleavage
- a periodate as an oxidizing agent.
- Such a synthetic pathway typically involves a multi-step synthesis and requires separation of most of the formed intermediates by means of column chromatography.
- etherified oxidized phospholipids have been similarly prepared by oxidizing an unsaturated bond of a fatty acid attached to a phospholipid backbone. More particularly, the etherified oxidized phospholipids were prepared, according to the teachings of this patent, by introducing an unsaturated short fatty acid to a glycerolipid, introducing a phosphate moiety to the obtained intermediate and oxidizing the unsaturated bond in the fatty acid chain by means of (i) hydrogen peroxide and formic acid, so as to obtain a diol, followed by potassium periodate, so as to obtain an aldehyde; or (ii) ozonolysis.
- esterified oxidized phospholipids prepared as above have the disadvantage of susceptibility to recognition, binding and metabolism of the active component in the body, making dosage and stability after administration an important consideration.
- Etherified oxidized phospholipids such as those described in U.S. Patent No. 6,838,452 and in WO 04/106486, exhibit higher biostability and high therapeutic activity.
- a method of preparing a compound having a glycerolic backbone and at least one oxidized moiety- containing residue attached to the glycerolic backbone via an ether bond which comprises: providing a first compound having a glycerolic backbone and at least one free hydroxyl group; providing a second compound having at least one unsaturated bond and at least one reactive group capable of forming an ether bond with the free hydroxyl group; reacting the first compound and the second compound to thereby obtain a third compound, the third compound having a glycerolic backbone and an unsaturated bond-containing residue being attached to the glycerolic backbone via an ether bond; isolating the third compound, to thereby obtain a purified third compound; reacting the purified third compound with an oxidizing agent, to thereby obtain a fourth compound, the fourth compound having a glycerolic backbone and an oxidized moiety-containing residue attached to the g
- reacting the first compound and the second compound is carried out in the presence of a base.
- the base is selected from the group consisting of sodium hydroxide, lithium hydroxide, calcium hydroxide, barium hydroxide and potassium hydroxide.
- the reactive group is a halide.
- isolating the third compound comprises: collecting the third compound; providing a solution of the third compound in a solvent, the solvent being selected such that the third compound is soluble therein whereby impurities formed during the reacting are insoluble therein, to thereby provide a mixture including the solution of the third compound in the solvent and insoluble impurities; removing the insoluble impurities; and removing the solvent, thereby obtaining the purified third compound.
- the solvent is selected from the group consisting of petrol ether, hexane and benzene.
- the oxidizing agent is selected from the group consisting of formic acid, hydrogen peroxide, a periodate, a perchlorate, a bismuthate, a permanganate, a chlorite, ozone, silver oxide, osmium tetraoxide and any combination thereof.
- the oxidized moiety is selected from the group consisting of a carboxylic acid, an ester, an aldehyde, an acetal, a ketal and a diol.
- the oxidized moiety is aldehyde and reacting the purified third compound with the oxidizing agent comprises: converting the purified third compound to a compound having a glycerolic backbone and a diol-containing residue attached to the glycerolic backbone via an ether bond; and oxidizing the compound having a glycerolic backbone and a diol-containing residue attached to the glycerolic backbone, to thereby obtain the fourth compound having a glycerolic backbone and an aldehyde- containing residue attached to the glycerolic backbone via an ether bond.
- the converting is effected by reacting the purified third compound with a first oxidizing agent selected from the group consisting of a peroxide, , a bismuthate, a periodate, a permanganate, and any combination thereof.
- a first oxidizing agent selected from the group consisting of a peroxide, , a bismuthate, a periodate, a permanganate, and any combination thereof.
- the oxidizing is effected by reacting the compound having a glycerolic backbone and a diol-containing residue attached to the glycerolic backbone with a second oxidizing agent selected from the group consisting of a periodate, a bismuthate, a permanganate, and a chlorite
- isolating the fourth compound comprises: collecting the fourth compound; providing a water-soluble adduct of the fourth compound; subjecting the water-soluble adduct to a biphasic system, to thereby provide an aqueous phase containing the adduct and an organic phase containing water-insoluble impurities formed during the reacting with the oxidizing agent; collecting the aqueous phase; decomposing the adduct; and collecting the fourth compound, thereby obtaining the purified fourth compound.
- providing the water-soluble adduct comprises: reacting the fourth compound with a Girard reagent.
- the oxidized moiety is a carboxylic acid and reacting the purified third compound with the oxidizing agent comprises: converting the purified third compound to a compound having a glycerolic backbone and an aldehyde-containing residue attached to the glycerolic backbone via an ether bond; and oxidizing the compound having a glycerolic backbone and an aldehyde-containing residue attached to the glycerolic backbone, to thereby obtain a compound having a glycerolic backbone and a carboxylic acid-containing residue attached to the glycerolic backbone via an ether bond.
- converting the purified third compound to the compound having a glycerolic backbone and an aldehyde-containing residue attached to the glycerolic backbone via an ether bond comprises: converting the purified third compound to a compound having a glycerolic backbone and a diol-containing residue attached to the glycerolic backbone via an ether bond; and oxidizing the compound having a glycerolic backbone and a diol-containing residue attached to the glycerolic backbone, to thereby obtain the compound having a glycerolic backbone and an aldehyde- containing residue attached to the glycerolic backbone via an ether bond.
- the method further comprises isolating the compound having a glycerolic backbone and an aldehyde-containing residue attached to the glycerolic backbone via an ether bond, to thereby obtain a purified compound having a glycerolic backbone and an aldehyde- containing residue attached to the glycerolic backbone via an ether bond.
- the isolating comprises: collecting the compound having a glycerolic backbone and an aldehyde-containing residue attached to the glycerolic backbone via an ether bond; providing a water-soluble adduct of the compound having a glycerolic backbone and an aldehyde-containing residue attached to the glycerolic backbone via an ether bond, as described hereinabove; subjecting the water-soluble adduct to a biphasic system, to thereby provide an aqueous phase containing the complex and an organic phase containing water-insoluble impurities formed during the converting and/or the oxidizing; collecting the aqueous phase; decomposing the adduct; and collecting the compound having a glycerolic backbone and an aldehyde-containing residue attached to the glycerolic backbone via an ether bond, thereby obtaining a purified compound having a glycerolic backbone and
- the oxidized moiety is a carboxylic acid and reacting the purified third compound with the oxidizing agent comprises: converting the purified third compound to a compound having a glycerolic backbone and an epoxide-containing residue attached to the glycerolic backbone via an ether bond; and oxidizing the compound having a glycerolic backbone and an epoxide-containing residue attached to the glycerolic backbone, to thereby obtain a compound having a glycerolic backbone and a carboxylic acid-containing residue attached to the glycerolic backbone via an ether bond.
- the converting comprises reacting the third compound with a peroxide.
- the oxidized moiety is a carboxylic acid and reacting the purified third compound with the oxidizing agent comprises reacting the purified third compound with a mixture of a permanganate and a periodate. According to still further features in the described preferred embodiments the said reacting is effected in the presence of a base.
- the first compound has at least two free hydroxyl groups, the method further comprising, prior to the reacting the first compound and the second compound: protecting at least one of the at least two groups with a protecting group.
- the protecting group is trityl.
- the first compound has at least two free hydroxyl groups
- the method further comprising, prior to the reacting the first compound and the second compound: protecting at least one of the at least two groups with a protecting group, preferably a trityl group.
- the method further comprises, prior to reacting the third compound and the oxidizing agent: replacing the trityl with a protecting group selected from the group consisting of acetate, pivaloate or benzoate.
- the compound having a glycerolic backbone and at least one oxidized moiety-containing residue attached to the glycerolic backbone further comprises a phosphorous- containing moiety attached to the glycerolic backbone
- the method further comprises, prior to reacting the first compound and the second compound, prior to isolating the third compound, prior to reacting the third compound with the oxidizing agent, prior to isolating the fourth compound or subsequent to isolating the fourth compound: reacting the first compound, the third compound, the purified third compound, the fourth compound or the purified fourth compound with a phosphorous-containing moiety, to thereby obtain the compound having a glycerolic backbone and at least one oxidized moiety-containing residue attached to the glycerolic backbone and further having a phosphorous-containing moiety attached to the glycerolic backbone.
- the at least one phosphorous-containing moiety is a phosphate moiety being attached to the glycerolic backbone via a phosphodiester bond.
- the at least one phosphorous-containing moiety is selected from the group consisting of phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4-phosphate, phosphoinositol-4,5-biposphonate, pyrophosphate, phosphoethanolamine-diethylenetriamine-pentaacetate, dinitrophenyl- phosphoethanolamine and phosphoglycerol.
- the phosphorous-containing moiety is attached to the sn-3 position of the glycerolic backbone of the compound.
- reacting the first compound, the third compound, the purified third compound, the fourth compound or the purified fourth compound with the phosphorous-containing moiety comprises: providing the first compound, the third compound, the purified third compound, the fourth compound or the purified fourth compound having a free hydroxyl group; reacting the first compound, the third compound, the purified third compound, the fourth compound or the purified fourth compound with a reactive phosphorous-containing compound having a second reactive group and a third reactive group, the second reactive group being capable of reacting with the free hydroxyl group and a second reactive group, to thereby provide the first compound, the third compound, the purified third compound, the fourth compound or the purified fourth compound having a reactive phosphorous-containing group attached to the glycerolic backbone; and converting the reactive phosphorous-containing group to the phosphorous-containing moiety.
- the reactive phosphorous-containing compound is phosphorous oxychlpride (POCl 3 ).
- the reacting is carried out in the presence of a base.
- the phosphorous-containing moiety is phosphoric acid
- the converting comprises hydrolyzing the reactive phosophrous-containing group.
- the phosphorous-containing moiety comprises an aminoalkyl group and the converting comprises reacting the reactive phosophrous-containing group with a derivative of the aminoalkyl group, the derivative being selected capable of reacting with the third reactive group.
- another method of preparing a compound having a glycerolic backbone and at least one oxidized moiety-containing residue attached to the glycerolic backbone via an ether bond comprising: providing a first compound having a glycerolic backbone and at least one free hydroxyl group; providing a fifth compound having at least one oxidized moiety and at least one fourth reactive group; reacting the first compound and the fifth compound to thereby obtain a reaction mixture containing a sixth compound, the sixth compound being the compound having a glycerolic backbone and at least one oxidized moiety-containing residue attached to the glycerolic backbone via an ether bond; and isolating the compound having a glycerolic backbone and at least one oxidized moiety-containing residue attached to the glycerolic backbone via an ether bond.
- reacting the first compound and the fifth compound is effected in the presence of a base.
- the base is selected from the group consisting of sodium hydride, lithium aluminum hydride, sodium amide, sodium hydroxide, potassium hydroxide and any mixture thereof.
- the fourth reactive group is a halide.
- the oxidized moiety is selected from the group consisting of a carboxylic acid, an ester, an acyl halide, an aldehyde, an acetal, a ketal and a diol
- the fifth compound comprises less than 4 carbon atoms. According to still further features in the described preferred embodiments the fifth compound comprises more than 5 carbon atoms.
- the first compound has at least two free hydroxyl groups, the method further comprising, prior to the reacting the first compound and the fifth compound: protecting at least one of the at least two groups with a protecting group.
- the protecting group is trityl.
- the compound having a glycerolic backbone and at least one oxidized moiety-containing residue attached to the glycerolic backbone further comprises a phosphorous- containing moiety attached to the glycerolic backbone
- the method further comprising, prior to or subsequent to reacting the first compound and the fifth compound, or subsequent to isolating the sixth compound: reacting the first compound or the sixth compound with a phosphorous-containing moiety, to thereby obtain the compound having a glycerolic backbone and at least one oxidized moiety-containing residue attached to the glycerolic backbone and further having a phosphorous-containing moiety attached to the glycerolic backbone, as described hereinabove.
- the first compound further comprises at least one alkylene chain having 1-30 carbon atoms.
- the alkylene chain is attached to the glycerolic backbone via an ether bond. According to still further features in the described preferred embodiments the alkylene chain is attached to the sn-1 position of the glycerolic backbone of the first compound.
- the oxidized moiety-containing residue is attached to the sn-2 position of the compound and further wherein at least one of the free hydroxyl groups of the glycerolic backbone is at the sn-2 position of the first compound.
- Ri is selected from the group consisting of H and a hydrocarbon chain having from 1 to 30 carbon atoms;
- R 3 is selected from the group consisting of hydrogen, alkyl, aryl, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl serine, phosphatidyl cardiolipin, phosphatidyl inositol, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphoryipropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N- [methoxy(propylene glycol)], phosphoinositol-4-phosphate, phosphoinositol-4,5- biposphonate, pyrophosphate, phosphoethanolamine-diethylenetriamine-pentacetate, dinitrophenyl-phosphoethanolamine, phosphoglycerol.
- a 2 is CH 2 ;
- R 1 is an alkyl having 1 -30 carbon atoms;
- X is an alkyl chain having 1-24 carbon atoms
- Y is selected from the group consisting of hydrogen, hydroxy, alkyl, alkoxy, halide, acetoxy and an aromatic functional group; and Z is selected from the group consisting of:
- R 4 being an alkyl or aryl
- R 3 is selected from the group consisting of hydrogen, alkyl, aryl, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl serine, phosphatidyl cardiolipin, phosphatidyl inositol, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N- [methoxy(propylene glycol)], phosphoinositol-4-phosphate, phosphoinositol-4,5- biposphonate, pyrophosphate, phosphoethanolamine-diethylenetriamine-pentacetate, dinitrophenyl-phosphoethanolamine, phosphoglycerol.
- a method of introducing a phosphate moiety into a compound having a glycerolic backbone and having an oxidized moiety-containing or a pre-oxidized moiety- containing residue attached thereto via an ether bond which comprises: providing a compound having a glycerolic backbone and an oxidized moiety- or a pre-oxidized moiety-containing residue attached to the glycerolic backbone via an ether bond and at least one a free hydroxyl group; reacting the compound a phosphorous-containing compound having a second reactive group and a third reactive, the second reactive group being capable of reacting with the free hydroxyl group, to thereby provide a compound having an oxidized moiety- or a pre-oxidized moiety-containing residue and a reactive phosphorous-containing group; and converting the reactive phosphorous-containing group to the phosphate moiety, thereby introducing the phosphate moiety into the compound.
- the compound having the glycerolic backbone comprises at least one alkylene chain having 1-30 carbon atoms.
- the alkylene chain is attached to the glycerolic backbone via an ether bond. According to still further features in the described preferred embodiments the alkylene chain is attached to the sn-1 position of the glycerolic backbone of the compound.
- the oxidized moiety is selected from the group consisting of carboxylic acid, ester, acyl halide, aldehyde, acetal, diol and ketal.
- the pre-oxidized moiety is an unsaturated moiety.
- the phosphorous-containing compound is POCl 3 .
- the reacting is performed in the presence of a base.
- the base is a tertiary amine.
- the phosphorous-containing compound is POCl 3
- the reactive phosphorous-containing group is a dichlorophosphate group.
- the compound having the glycerolic backbone has a pre-oxidized moiety-containing residue attached thereto via an ether bond.
- the phosphate moiety is selected from the group consisting of phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, phosphoryl cardiolipin, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4-phosphate, phosphoinositol-4,5-biposphonate, pyrophosphate, phosphoethanolamine-diethylenetriamine-pentaacetate, dinitrophenyl- phosphoethanolamine, phosphoglycerol.
- the phosphate moiety is phosphoric acid and the converting comprises hydrolyzing the reactive phosphorous-containing group.
- the phosphate moiety comprises an alkylamino group and the converting comprises reacting the reactive phosphorous-containing moiety with a derivative of an aminoalkyl, the derivative being capable of reacting with the reactive phosphorous- containing group.
- a 2 is CH 2 ;
- R 1 is an alkyl having 1-30 carbon atoms;
- R 2 is
- X is an alkyl chain having 1-24 carbon atoms
- Y is selected from the group consisting of hydrogen, hydroxy, alkyl, alkoxy, halide, acetoxy and an aromatic functional group
- Z is selected from the group consisting of:
- R 4 being an alkyl or aryl
- R 3 is selected from the group consisting of hydrogen, alkyl, aryl, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl serine, phosphatidyl cardiolipin, phosphatidyl inositol, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N- [methoxy(propylene glycol)] , phosphoinositol-4-phosphate, phosphoinositol-4,5-biposphonate, pyrophosphate, phosphoethanolamine- diethylenetriamine-pentacetate, dinitrophenyl-
- isolating the third compound comprises: collecting the third compound; providing a solution of the third compound in a solvent, the solvent being selected such that the third compound is soluble therein whereby impurities formed during the reacting are insoluble therein, to thereby provide a mixture including the solution of the third compound in the solvent and insoluble impurities; removing the insoluble impurities; and removing the solvent, thereby obtaining the purified third compound.
- the oxidized moiety is selected from the group consisting of a carboxylic acid and an ester.
- the oxidizing agent comprises a mixture of a periodate and a permanganate.
- reacting the purified third compound with an oxidizing agent is effected in the presence of a base.
- R 3 is hydrogen
- the method further comprising, prior to the reacting the first compound and the second compound: protecting a free hydroxyl group at position sn- 3 of the glycerolic backbone with a protecting group.
- the compound having a glycerolic backbone and at least one oxidized moiety-containing residue attached to the glycerolic backbone further comprises a phosphorous- containing moiety attached to the glycerolic backbone, such that R 3 is selected from the group consisting of phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl serine, phosphatidyl cardiolipin, phosphatidyl inositol, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N- [methoxy(propylene glycol)], phosphoinositol-4-phosphat
- the at least one phosphorous-containing moiety is a phosphate moiety being attached to the glycerolic backbone via a phosphodiester bond.
- reacting the purified fourth compound with the phosphorous-containing moiety comprises: providing the purified fourth compound having a free hydroxyl group; reacting the purified fourth compound with a reactive phosphorous-containing compound having a second reactive group and a third reactive group, the second reactive group being capable of reacting with the free hydroxyl group and a second reactive group, to thereby provide the first compound, the third compound, the purified third compound, the fourth compound or the purified fourth compound having a reactive phosphorous-containing group attached to the glycerolic backbone; and converting the reactive phosphorous-containing group to the phosphorous- containing moiety.
- the reactive phosphorous-containing compound is phosphorous oxychloride (POCI 3 ).
- POCI 3 phosphorous oxychloride
- mixture describes a mixture that includes more than one substance and which can be in any form, for example, as a homogenous solution, a suspension, a dispersion, a biphasic solution and more.
- the terms “comprising”, “including” and “containing” means that other steps and ingredients that do not affect the final result can be added. These terms encompass the terms “consisting of and “consisting essentially of.
- the phrase “consisting essentially of” means that the composition or method may include additional ingredients and/or steps, but only if the additional ingredients and/or steps do not materially alter the basic and novel characteristics of the claimed composition or method.
- the term “method” or “process” refers to manners, means, techniques and procedures for accomplishing a given task including, but not limited to, those manners, means, techniques and procedures either known to, or readily developed from known manners, means, techniques and procedures by practitioners of the chemical, pharmacological, biological, biochemical and medical arts.
- phospholipid is used herein to collectively describe compounds that include a non-polar lipid group and a highly polar end phosphate group.
- phosphoglycerides family of compounds.
- phospholipid is therefore typically used herein throughout to describe phosphoglycerides, unless otherwise indicated.
- phosphoglyceride is therefore used herein to describe compounds having a glycerol backbone, one or more lipid moieties and one or more phosphate end group, which are attached to the glycerolic backbone.
- Most of the naturally- occurring glycerolipids include two lipid moieties attached to the sn-1 and sn-2 positions and one phosphate moiety attached to the sn-3 position of the glycerol backbone.
- oxidized phospholipid is therefore used herein to describe a phospholipid, as well as a phosphoglyceride, which includes one or more oxidized moieties, as this term is described hereinbelow.
- the oxidized moiety is included within a lipid moiety.
- glycolipid describes a compound having a glycerolic backbone and one or two lipid moieties attached thereto.
- the lipid moieties can be attached to the glycerol backbone via an ester and/or an ether bond.
- lipid describes a hydrocarbon residue having 3-30 carbon atoms.
- the lipids in phospholipids and glycerolipids are derived from fatty acids and are therefore attached to the backbone via an O-acyl (ester) bond.
- the lipid moiety can be attached to the backbone either via and ether or an ester bond.
- the terms "mono-esterified” and “di-esterified” with respect to phospholipids or glycerolipids describe phospholipids or glycerolipids, either oxidized or non-oxidized, in which one or two of the lipid moieties, respectively, are attached to the glycerol backbone via an ester (e.g., O-fatty acyl) bond.
- ester e.g., O-fatty acyl
- the terms "mono-etherified” and “di-etherified” with respect to phospholipids or glycerolipids describe phospholipids or glycerolipids, either oxidized or non-oxidized, in which one or two of the lipid moieties, respectively, are attached to the glycerol backbone via an ether bond.
- phosphoglycerol describes a compound having a glycerolic backbone and a phosphate group attached to one position thereof.
- phosphoglycerides describes a compound having a glycerolic backbone, one or two lipid moieties and a phosphate moiety attached thereto.
- mono-etherified phosphoglyceride describes a phosphoglyceride, in which a lipid moiety is attached to the glycerolic backbone via an ether bond.
- moiety describes a functional substance or group which forms a part of a compound.
- the present invention is of novel methods of preparing oxidized phospholipids which can be efficiently used for a scaled up production of such oxidized phospholipids.
- the present invention is of novel methods of introducing an oxidized moiety to a compound having a glycerolic backbone and is further of novel methods of introducing a phosphorous-containing moiety to such a compound.
- the novel methods described herein are devoid of column chromatography and typically use commercially available and environmental friendly reactants.
- oxidized phospholipids can regulate the immune response to oxidized LDL and are thus highly effective in treating atherosclerosis and related diseases, as well as autoimmune diseases and inflammatory disorders. It has been further reported that generally, etherified oxidized phospholipids are superior to comparable esterified oxidized phospholipids as therapeutic agents. These highly beneficial oxidized phospholipids typically include a glycerolic backbone, to which a lipid residue, a phosphate residue and an oxidized moiety- containing lipid residue are attached, as is described in detail, for example, in U.S. Patent No. 6,838,452 and in WO 04/106486.
- a method of preparing a compound having a glycerolic backbone and at least one oxidized moiety-containing residue attached to the glycerolic backbone via an ether bond which is devoid of column chromatography.
- the method is effected by: providing a first compound having a glycerolic backbone and at least one free hydroxyl group; providing a second compound having at least one unsaturated bond and at least one reactive group capable of forming an ether bond with said free hydroxyl group; reacting the first compound and the second compound to thereby obtain a third compound, which has a glycerolic backbone and an unsaturated bond-containing residue being attached to the glycerolic backbone via an ether bond; isolating the third compound, to thereby obtain a purified third compound; reacting the purified third compound with an oxidizing agent, to thereby obtain a fourth compound, which has a glycerolic backbone and an oxidized moiety- containing residue attached to the glycerolic backbone via an ether bond; and isolating the fourth compound to thereby obtain a purified fourth compound, thereby obtain the compound having a glycerolic backbone and
- a compound having a glycerolic backbone which is also referred to herein interchangeably as “a glycerolic compound”, or a “glycerol compound” describes a compound that includes the following skeleton:
- each of the glycerolic positions sn-1, sn-2 and sn-3 is substituted by a free hydroxyl group.
- oxidized moiety and "an oxidized moiety-containing residue", which are used herein interchangeably, describe an organic moiety in which at least one of its carbon atoms is substituted by an oxygen atom. Examples, without limitation, include aldehyde, carboxylic acid, carboxylic ester, diol, acetal, and ketal.
- a compound having an oxidized moiety- containing residue and “an oxidized moiety-containing compound” are also used herein interchangeably.
- the method according to this aspect of the present invention is based on introducing an unsaturated moiety to the glycerolic compound and subjecting the unsaturated bond to oxidative cleavage.
- a first compound which has a glycerolic backbone and at least one free hydroxyl group, is selected as the starting material.
- a compound that has an unsaturated moiety and a first reactive group which is also referred to herein as the second compound, is obtained, either commercially or using methods known in the art, and is reacted with the glycerolic starting material.
- the first reactive group is selected capable of reacting with the free hydroxyl group. Reacting with the free hydroxyl group so as to form an ether bond is typically performed via a nucleophilic mechanism and therefore the first reactive group is preferably characterized as a good leaving group and can be, for example, halide, sulfonate, and any other leaving group.
- the reactive group is halide and more preferably, it is bromide.
- the second compound is preferably selected such that the unsaturated moiety is present at a terminus position thereof, so as to facilitate the oxidation reaction that follows.
- unsaturated moiety it is meant herein a moiety that includes at least two carbon atoms that are linked therebetween by an unsaturated bond, e.g., a double bond or a triple bond, preferably a double bond.
- the second compound comprises from 4 to 30 carbon atoms, more preferably from 4 to 27 carbon atoms, more preferably from 4 to 16 carbon atoms, more preferably from 4 to 10 carbon atoms, more preferably from 4 to
- the second compound comprises 6 carbon atoms.
- Suitable bases for use in this context of the present invention include, without limitation, inorganic bases such as sodium hydroxide, lithium hydroxide, calcium hydroxide, barium hydroxide and potassium hydroxide.
- Reacting the first compound and the second compound is typically performed in the presence of a solvent.
- Suitable solvents for use in this context of the present invention include, without limitation, non polar solvents such as petrol ether, hexane, benzene and toluene.
- the method according to this aspect of the present invention optionally and preferably further comprises, prior to reacting the first compound and the second compound, protecting one or more additional free hydroxyl groups that may be present within the first compound.
- the protecting group is trityl.
- Trityl is a bulky group, which typically serves as a selective protecting group, due to steric hindrance. Thus, while reacting a glycerolic compound that has more than one free hydroxyl group, typically, the trityl group would be reacted with the less hindered group.
- trityl group as the protecting group while introducing the above-described second compound to the glycerolic backbone is highly beneficial, since due to its bulkiness, protection of the hydroxyl end groups, at the sn-1 and/or an-3 positions would be effected, leaving the hydroxyl group at the sn-2 available for further substitutions.
- reaction mixture which contains a compound that has a glycerolic backbone and an unsaturated moiety-containing residue attached thereto via an ether bond is obtained.
- a compound is also referred to herein interchangeably as a third compound.
- the third compound can further include one or more protecting groups, protecting free hydroxyl groups that may be present within the glycerolic backbone.
- the third compound is then isolated from the reaction mixture and treated so as to obtain a purified compound.
- isolating the third compound is performed by first collecting the formed third compound. Collecting the third compound is typically performed using conventional techniques such as extraction, removal of the solvent, filtration and the like, including any combination thereof. Once collected, the crude product is dissolved is a solvent, whereby the solvent is selected such that the third compound is soluble therein whereby impurities formed during the reaction between the first and the second compounds are insoluble therein.
- impurities is used herein to describe any substance that is present in the final crude product and is not the product itself and include, for example, unreacted starting materials and side products.
- Suitable solvents for use in this context of the present invention include, without limitation, non-polar solvents such as petrol ether, hexane, benzene, heptane and toluene.
- non-polar solvents such as petrol ether, hexane, benzene, heptane and toluene.
- the solvent is petrol ether.
- the solvent is hexane.
- the insoluble impurities are then removed from the mixture, preferably by filtration, the solvent is removed and a purified third compound is obtained while circumventing the need to use column chromatography in the purification procedure thereof.
- the purified third compound is then reacted with an oxidizing agent, so as to oxidize the unsaturated moiety and thereby obtain a fourth compound, in which an oxidized moiety-containing residue is attached to the glycerolic backbone via an ether bond.
- the oxidizing agent is selected depending on the desired oxidized moiety, as is detailed hereinbelow, and can be, for example, a peroxide, a periodate, a bismuthate, a permanganate, a chlorite, ozone, silver oxide, osmium tetraoxide and any combination thereof.
- a peroxide a periodate, a bismuthate, a permanganate, a chlorite, ozone, silver oxide, osmium tetraoxide and any combination thereof.
- periodate a compound having the formula
- X can be hydrogen (for periodic acid) or a monovalent cation of a metal (e.g., sodium, potassium).
- a preferred periodate is sodium periodate (NaIO 4 ).
- bismuthate describes a compound having the formula XBiO 3 , wherein X can be hydrogen or a monovalent cation of a metal (e.g., sodium, potassium).
- permanganate describes a compound having the formula XMnO 4 , wherein X can be hydrogen or a monovalent cation of a metal (e.g., sodium, potassium). Preferred permanganate is potassium permanganate (KMnO 4 ).
- chlorite describes a compound having the formula XClO 2 , wherein X can be hydrogen or a monovalent cation of a metal (e.g., sodium, potassium).
- peroxide include a compound having the formula R-0-0-H, wherein R can be hydrogen, alkyl, cycloalkyl, aryl, oxyalkyl, oxycycloalkyl and oxyaryl, as these terms are defined herein.
- alkyl refers to a saturated aliphatic hydrocarbon including straight chain and branched chain groups.
- the alkyl group has 1 to 20 carbon atoms.
- a “cycloalkyl” group refers to an all-carbon monocyclic or fused ring (i.e., rings which share an adjacent pair of carbon atoms) group wherein one of more of the rings does not have a completely conjugated pi-electron system.
- examples, without limitation, of cycloalkyl groups are cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexadiene, cycloheptane, cycloheptatriene, and adamantane.
- An “aryl” group refers to an all-carbon monocyclic or fused-ring polycyclic
- aryl groups i.e., rings which share adjacent pairs of carbon atoms
- aryl groups are phenyl, naphthalenyl and anthracenyl.
- the peroxide is hydrogen peroxide or a peroxycarboxylic acid (e.g., perbenzoic acid).
- a peroxycarboxylic acid e.g., perbenzoic acid
- the oxidized moiety is aldehyde and reacting the third compound with an oxidizing agent is performed by first converting the unsaturated moiety in the third compound to a diol moiety, preferably by means of an oxidizing agent, which is referred to herein as a first oxidizing agent; and then further oxidizing the diol moiety, by means of a second oxidizing agent, to the aldehyde moiety.
- the first and the second oxidizing agents can be the same or different and can be, for example, a peroxide, a periodate, a bismuthate, a permanganate, a chlorite, ozone and any combination thereof.
- Suitable oxidizing agents that can be used in this respect include oxidizing agents that are capable of inducing an oxidative cleavage of an unsaturated moiety such as, for example, ozone, osmium tetraoxide, and potassium permanganate.
- the first oxidizing agent is a peroxide, such as hydrogen peroxide and the second oxidizing agent is, for example, a periodate or a bismuthate.
- reaction conditions at which the converting and oxidizing procedures are performed are determined in accordance with the oxidizing agent used.
- the first and the second oxidizing agents are different and converting the unsaturated moiety to a diol moiety and oxidizing the diol moiety are performed sequentially.
- the protecting group, if present, is removed so as to obtained a compound having three or more free hydroxyl groups (herein, a triol).
- Such a compound can be easily purified, prior to its oxidation to an aldehyde, by means of crystallization, due to its unique chemical features, as is demonstrated in the Examples section the follows (see, Example 1). Once purified, selective protection the free hydroxyl group at the sn-1 and/or sn-3 positions can be effected, prior to the next synthetic step.
- the thus formed aldehyde-containing glycerolic compound is then isolated from the reaction mixture and purified.
- the aldehyde is purified by means of forming a water-soluble adduct thereof.
- the aldehyde- containing fourth compound is collected using conventional techniques as described herein above and thereafter the crude product is converted into a water-soluble adduct thereof.
- an aqueous phase that contains the water-soluble adduct and an organic phase, which contains water- insoluble impurities are obtained. Since most of the side products and unreacted material formed during the oxidation reaction are organic substances, such substances are easily separated from the water-soluble adduct by collecting the aqueous phase.
- the aldehyde-containing compound is thereafter recovered by decomposing the water-soluble adduct.
- Suitable water-soluble adducts that can be used in this context of the present invention are preferably obtained by reacting the aldehyde-containing compound with a Girard reagent.
- Girard reagents are a family of substances that are capable of forming water- soluble hydrazone adducts with carbonyl-containing compounds, and thus allow the separation of carbonyl-containing compounds from other organic non-carbonylic compounds.
- Girard reagents are ionic derivatives of semicarbazide.
- the T form is (Carboxymethyl)trimethylammonium chloride hydrazide:
- the D form is (Carboxymethyl)dimethylammonium chloride hydrazide:
- reacting the third compound with an oxidizing agent can be performed by first providing an aldehyde- containing compound, optionally and preferably as described hereinabove, and further optionally and preferably, by providing a purified aldehyde-containing compound, using the methodology described hereinabove, and thereafter further oxidizing the aldehyde to carboxylic acid.
- Oxidizing the aldehyde to a carboxylic acid is preferably performed by reacting the aldehyde with an oxidizing agent such as chlorite.
- the unsaturated moiety can be oxidized to a carboxylic acid via an epoxide intermediate.
- reacting the third compound with an oxidizing agent can be performed by converting the unsaturated moiety to epoxide, and converting the epoxide to the carboxylic acid.
- converting the epoxide to a carboxylic acid is performed by converting the epoxide to diol and oxidizing the diol so as to obtain the carboxylic acid moiety.
- Converting the third compound to an epoxide is preferably performed by reacting the third compound with a peroxide, as defined hereinabove, and more preferably with a peroxycarboxylic acid.
- Converting the epoxide to diol is preferably performed by reacting the epoxide with perchloric acid (HClO 4 ).
- the epoxide is converted to diol by reacting it with sulfuric acid.
- the diol is then converted to the carboxylic acid by reacting it with a third oxidizing agent.
- the third oxidizing agents can be selected from periodate, bithmutate, permanganate, chlorite and any combination thereof.
- the diol is converted to the carboxylic acid by reacting it with a periodate, followed by a chlorite.
- the fourth compound thus obtained having a glycerolic backbone and a carboxylic acid-containing moiety attached thereto via an ether bond, in then purified, so as to obtain a purified product.
- the present inventors have now surprisingly found that a fourth compound obtained via the epoxide intermediate can be easily purified, while avoiding the use of column chromatography, if a free hydroxyl group thereof is protected by a protecting group such as acetate, pivaloate or benzoate.
- a free hydroxyl group if present in the glycerol backbone, is preferably protected, whereby a preferable, selective protecting group is trityl.
- trityl is a large, bulky and non-polar moiety, its presence might, in some cases, complicate the isolation and purification procedures of the various intermediates and the final product.
- trityl group limitations associated with the trityl group can be readily circumvented by: (i) isolating an aldehyde-containing compound via the formation of a water-soluble adduct thereof, as is widely described hereinabove; or (ii) replacing the trityl protecting group by a less bulky group, subsequent to the introduction of the second compound.
- oxidizing the third compound comprises the formation of a diol
- the trityl protecting group can be removed and the resulting triol can be isolated by means of crystallization.
- the process further comprises, subsequent to the provision of the purified third compound and/or prior to reacting the third compound with an oxidizing agent: replacing the trityl group with a protecting group selected from the group consisting of acetate, pivaloate or benzoate.
- Replacing the trityl protecting group is typically effected by removing the trityl group, so as to obtain a free hydroxy 1 group and protecting the hydroxyl group with the desired protecting group.
- Protecting the hydroxyl group with an acetate group is readily performed by reacting the third compound with e.g., acetic anhydride.
- Protecting the hydroxyl group with a pivaloate group is readily performed by reacting the third compound with e.g., pivaloyl chloride.
- Protecting the hydroxyl group with a benzoate group is readily performed by reacting the third compound with e.g., benzoyl choride.
- Purifying a fourth compound, as described herein, which has an acetate, pivaloate or benzoate protecting group can be carried out by conventional extraction techniques, preferably while using silica gel during the extraction procedure.
- silica gel As is demonstrated in the Examples section that follows (see, Example 2), it was found that preparing a glycerolic compound having an oxidized moiety- containing group attached thereto via an ether bond, via the formation of an epoxide- containing intermediate that has an acetate protecting group, resulted in highly purified compound and high reaction yield.
- the present inventors have further uncovered that a fourth compound having a carboxylic acid as an oxidized moiety can be readily obtained by reacting the third compounds described herein with a mixture of a periodate and a permanganate as an oxidizing agent.
- the oxidizing agent utilized in this route comprises safe, non-hazardous agents.
- the oxidized moiety is carboxylic acid and oxidizing the third compound is effected by reacting the third compound with a mixture of a periodate and a permanganate. Such a reaction is preferably performed in the presence of a base.
- bases that are suitable for use in this embodiment of the present invention include sodium carbonate and sodium bicarbonate.
- the obtained fourth compound has a protecting group, as described hereinabove, once the fourth compound is obtained, isolated and optionally purified, the protecting group is removed.
- the fourth compound can be readily isolated upon removal of the protecting group and obtaining a compound that has a carboxylic moiety and a hydroxy moiety.
- the fourth compound can be readily purified by dissolving it in a solvent, whereby the solvent is selected such that the fourth compound is soluble therein whereby impurities formed during the oxidation process are insoluble therein. Moreover, such a solvent can be selected such that the fourth compound is soluble therein whereby the protecting group is insoluble therein.
- Suitable solvents for use in this context of the present invention include, without limitation, non-polar solvents such as petrol ether, hexane, benzene, heptane and toluene, semi-polar solvents such as ethyl acetate and mixtures thereof.
- the solvent is petrol ether or hexane and/or a mixture of thereof with ethyl acetate.
- the insoluble impurities are then removed from the mixture, preferably by filtration, the solvent is removed and a purified fourth compound is obtained while circumventing the need to use column chromatography in the purification procedure thereof and further circumventing the need for multiple purification procedures of the various intermediates formed.
- the process is effected by providing a carboxylic-acid containing compound and then converting the carboxylic acid to the ester. This can be readily carried out, using procedures well known in the art. Exemplary procedures are described in the Examples section that follows (see, for example, Examples 1, 6 and 7).
- compounds having a glycerolic backbone and at least one oxidized moiety-containing residue attached to the glycerolic backbone and further having a phosphorous-containing moiety attached to the glycerolic backbone, preferably a phosphate-containing moiety are known as oxidized phospholipids and are highly beneficial in treating various conditions.
- the process described herein optionally and preferably further comprises introduction of such a phosphorous-containing moiety to the glycerolic backbone.
- the phrase "phosphorous-containing moiety” describes a moiety, as defined herein, which includes one or more phosphor atoms. Representative examples include, without limitation, phosphates, phosphonates, phosphines, phosphine oxides, phosphites, pyrophosphates and like.
- phosphinyl describes a -PR 1 R" group, with R' and R" as defined hereinabove.
- the introduction of a phosphorous-containing moiety to the glycerolic compound can be performed either prior to reacting the first compound and the second compound, prior to isolating the third compound, prior to reacting the third compound with the oxidizing agent, prior to isolating the fourth compound or subsequent to isolating the fourth compound, and can be performed using any of the methods known in the art.
- Introduction of a phosphorous-containing moiety to a compound having a glycerolic compound is therefore performed by: reacting any of the first compound, the third compound, the purified third compound, the fourth compound or the purified fourth compound described above, with a phosphorous-containing moiety, so as to obtain a compound having a glycerolic backbone and at least one oxidized moiety-containing residue attached to the glycerolic backbone and further having a phosphorous-containing moiety attached to the glycerolic backbone.
- the phosphorous-containing moiety is a phosphate moiety which is attached to the glycerolic backbone via a phosphodiester bond.
- the phosphorous-containing moiety can be, for example, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-[methoxy(propylene glycol)], phosphoinositol-4-phosphate, phosphoinositol-4,5-biposphonate, pyrophosphate, phosphoethanolamine-diethylenetriamine-pentaacetate, dinitrophenyl- phosphoethanolamine and phosphoglycerol.
- the phosphorous-containing moiety is attached to the sn-3 position of the glycerolic backbone and thus, introduction of such a moiety is performed selectively, by appropriately protecting other free hydroxyl groups that are present in the reacting compound or deprotecting a protected hydroxyl group at the desired position.
- the phosphorous-containing moiety is typically introduced prior to the provision of an oxidized-moiety containing compound.
- the phosphorous-containing moiety is phosphoryl choline
- the presently known methods involve N-alkylation reactions, which involve hazardous and environmentally unfriendly reagents such as, for example, trimethylamine.
- a phosphorous-containing moiety can be readily introduced subsequent to the provision of an oxidized moiety- containing compound; and (ii) the introduction of the phosphorous-containing moiety can be efficiently performed via a reactive phosphorous-containing intermediate.
- the present inventors have designed and successfully practiced a novel process for introducing a phosphorous-containing moiety to compounds having a glycerolic backbone and an oxidized moiety-containing residue attached thereto via an ether bond.
- This process combined with the process described above for preparing the oxidized moiety-containing compound, can be beneficially used for preparing the therapeutically beneficial oxidizes phospholipids described above.
- the introduction of the phosphorous-containing moiety is performed subsequent to the production of the third compound or subsequent to the production of the fourth compound, with the latter being preferred.
- the process of introducing the phosphorous-containing moiety presented herein is also applicable at any other stage.
- the introduction of a phosphorous-containing moiety to a glycerolic compound is therefore preferably effected, according to the present embodiments, by reacting a first compound, a third compound, a purified third compound, a fourth compound or a purified fourth compound as described above, which has a free hydroxyl group, with a reactive phosphorous-containing compound, so as to produce a compound having a reactive phosphorous-containing group; and converting the reactive phosphorous-containing group to the phosphorous-containing moiety.
- the reactive phosphorous-containing compound is selected such that upon said reacting, a reactive phosphorous-containing group attached to the glycerolic backbone is obtained.
- the reactive phosphorous-containing compound is therefore selected as having a second reactive group and a third reactive group, whereby the second reactive group is selected capable of reacting with the free hydroxyl group and the third reactive group is selected capable of being converted to the phosphorous- containing moiety.
- Reactive groups that are capable of reacting with a free hydroxyl groups include, for example halides, sulfonyl chlorides, acyl halides and the like.
- the second reactive group is halide and more preferably it is chloride.
- preferable phosphorous-containing moieties are phosphate moieties
- converting the phosphorous-containing compound to the desired phosphorous-containing moiety typically involves a formation of a phosphate- ester bond. Such a bond can be obtained, for example, by reacting a phosphoric derivative such as phosphoryl chloride with a hydroxy-containing moiety.
- the reactive phosphorous- containing compound is phosphorous oxychloride (POCl 3 ), such that the third and the second reactive groups are both chlorides and the compound having a phosphorous- containing reactive group has a glycerolic backbone and a phosphoryl chloride residue attached thereto.
- Reacting the first compound, the third compound, the purified third compound, the fourth compound or the purified fourth compound with the phosphorous oxychloride is typically carried out in the presence of a base.
- Suitable bases include organic and inorganic bases, with organic bases being preferred.
- the reaction is preferably effected in presence of a base such as, for example, trialkylamine (e.g., triethylamine).
- This reaction is further preferably carried out in the presence of a solvent, preferably a polar solvent such as THF.
- a solvent preferably a polar solvent such as THF.
- the phosphoryl chloride-containing glycerolic containing compound obtained by the process described herein can be readily converted to any desired phosphorus- containing moiety and is therefore a highly beneficial intermediate.
- it can be converted to phosphoric acid by a simple hydrolysis thereof, as is exemplified in the Examples section that follows.
- it can be reacted with a hydroxy-containing moiety, and optionally and preferably also with water, to thereby obtain other phosphate moieties.
- Preferred phosphate moieties that are incorporated in therapeutic oxidized phospholipids typically include an aminoalkyl group, which can be further N-alkylated.
- Converting the phosphoryl chloride intermediate to such phosphate moieties can thus be readily performed by reaction with a derivative of the desired aminoalkyl group, selected capable of reacting with the third reactive group (being a chloride).
- aminoalkyl-containing phosphate moieties can be obtained by reacting the phosphoryl chloride intermediate with an aminoalcohol. If desired, the aminoalcohol can thereafter be further alkylated, so as to produce an N-alkylated aminoalkyl phosphate moiety, as in the case of a phosphoryl choline moiety.
- N-alkylated aminoalkyl phosphate moiety attached to a glycerolic backbone using the process described above is highly beneficial since it circumvents the need to use hazardous materials such as the trimethylamine typically used for obtaining such compounds.
- the introduction of the phosphorous-containing moiety can be performed either prior to or subsequent to the introduction of an oxidized moiety-containing residue to the glycerolic compound.
- a phosphoryl choline moiety was successfully introduced into glycerolic compounds having either an oxidized-moiety containing residue or an unsaturated-moiety containing residue (see, Examples 4 and 5).
- the process of introducing a phosphate moiety via a reactive phosphorous-containing intermediate presented herein can be performed either with glycerolic compounds having an oxidized or pre-oxidized moiety attached thereto via an ether bond.
- the present inventors have further designed and practiced an additional process for preparing a glycerolic compound having an oxidized moiety attached thereto via an ether bond, which is effected by direct introduction of an oxidized moiety-containing residue to a glycerolic compound.
- a method of preparing a compound having a glycerolic backbone and at least one oxidized moiety-containing residue attached to the glycerolic backbone via an ether bond which is effected by: providing a first compound having a glycerolic backbone and at least one free hydroxyl group, as described hereinabove; providing a fifth compound having at least one oxidized moiety, as described hereinabove, and at least one fourth reactive group; reacting the first compound and the fifth compound to thereby obtain a reaction mixture containing a sixth compound, being the compound having a glycerolic backbone and at least one oxidized moiety-containing residue attached to the glycerolic backbone via an ether bond; and isolating the compound having a glycerolic backbone and at least one oxidized moiety-containing residue attached to the glycerolic backbone via an ether bond.
- the process according to this aspect of the present invention therefore involves the reaction of the first compound described hereinabove with a compound that has a reactive group that is capable of reacting with a free hydroxyl group of the first compound, referred to herein as a fourth reactive group, and an oxidized moiety.
- a compound that has a reactive group that is capable of reacting with a free hydroxyl group of the first compound referred to herein as a fourth reactive group, and an oxidized moiety.
- a compound that has a reactive group that is capable of reacting with a free hydroxyl group of the first compound referred to herein as a fourth reactive group, and an oxidized moiety.
- a compound that has a reactive group that is capable of reacting with a free hydroxyl group of the first compound referred to herein as a fourth reactive group, and an oxidized moiety.
- Such a compound is referred to herein as the fifth compound.
- the oxidized moiety in the fifth compound can be any of the oxidized moieties described above, namely, an aldehyde, a diol, a carboxylic acid, an ester an acetal or a ketal.
- the oxidized moiety can be a semi-oxidized moiety, namely, being readily converted to a desired oxidized moiety without reacting with an oxidizing agent.
- An example of such a semi-oxidized moiety is nitrile, which can be readily converted to a carboxylic acid by a simple hydrolysis.
- the fourth reactive group in the fifth compound is as described herein for the first reactive group and is preferably a halide and more preferably a bromide.
- Reacting the first compound and the fifth compound is preferably effected in the presence of a base.
- a base Relatively strong inorganic bases such as, for example, sodium hydride, potassium hydroxide, lithium aluminum hydride, sodium amide, sodium hydroxide and any mixture thereof are preferred.
- a fifth compound which has 4 or 5 carbon atoms might be cyclized during the reaction, thus adversely affecting the reaction efficiency.
- the fifth compound preferably has less than 4 or more than 5 carbon atoms.
- the hydroxyl group is optionally and preferably protected by a protecting group, prior to reacting the first and the fifth compounds.
- the protecting group can be removed and the compound is purified using conventional purification methods.
- the process according to this aspect of the present invention is highly beneficial since it enables to prepare the described oxidized moiety-containing compound in a one-step synthesis.
- oxidized phospholipids can be readily obtained by introducing a phosphorous-containing moiety, a described in detail hereinabove, either prior to or subsequent to the reaction with the fifth compound.
- the introduction of the phosphorous-containing moiety is preferably performed using the process presented hereinabove.
- the first compound can include an alkylene chain attached thereto.
- the alkylene chain is attached to the sn-1 position of the first compound.
- the alkylene chain can be attached to the glycerolic compound by, for example, an ester bond or an ether bond.
- the alkylene chain is attached via an ether bond, such that the final product is a dietherified glycerolic compound.
- the first compound is a glycerolipid, as defined herein and preferably, a mono-etherified glycerolipid in which the lipid moiety is attached to the sn-1 position of the glycerol.
- a first compound therefore has one free hydroxyl group, which, as described hereinabove, is preferably protected prior to any reaction.
- the first compound can be, for example, a glycerol, a glycerolipid, a mono-etherified glycerolipid, a di-etherified glycerolipid, a phosphoglycerol, a phosphoglyceride, a mono-etherified phosphoglyceride and a lysolechitin.
- the position at which the oxidized moiety-containing residue is attached to the glycerolic backbone affects the activity of the resulting compounds and thus, as is further discussed hereinabove, it is preferably to perform the reaction selectively.
- the oxidized moiety- containing residue is attached to the sn-2 position of the compound.
- selective attachment of the oxidized moiety-containing residue is performed.
- the first compound therefore has the following general formula I:
- Ri is selected from the group consisting of H and a hydrocarbon chain having from 1 to 30 carbon atoms;
- R 3 is selected from the group consisting of hydrogen, alkyl, aryl, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl serine, phosphatidyl cardiolipin, phosphatidyl inositol, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-
- a 2 is CH 2 ;
- Ri is an alkyl having 1-30 carbon atoms
- X is an alkyl chain having 1-24 carbon atoms
- Y is selected from the group consisting of hydrogen, hydroxy, alkyl, alkoxy, halide, acetoxy and an aromatic functional group; and Z is selected from the group consisting of:
- R 3 is selected from the group consisting of hydrogen, alkyl, aryl, phosphoric acid, phosphoryl choline, phosphoryl ethanolamine, phosphoryl serine, phosphatidyl choline, phosphatidyl ethanolamine, phosphatidyl serine, phosphatidyl cardiolipin, phosphatidyl inositol, phosphoryl cardiolipin, phosphoryl inositol, ethylphosphocholine, phosphorylmethanol, phosphorylethanol, phosphorylpropanol, phosphorylbutanol, phosphorylethanolamine-N-lactose, phosphoethanolamine-N-
- oxidized phospholipids and particularly therapeutically beneficial oxidized phospholipids such as l-hexadecyl-2-(4'- carboxy)butyl-3-phosphocholine (also known in the art and referred to herein as CI- 201).
- CI- 201 l-hexadecyl-2-(4'- carboxy)butyl-3-phosphocholine
- 1- Hexadecyl-2-(4'-carboxy)butyl-3-phosphocholine was produced in an industrial scale of dozens of Kg.
- an unsaturated moiety is introduced into a glycerolic backbone and is thereafter oxidized by means of formic acid, hydrogen peroxide and periodate. Then thus formed oxidized product is purified by means of a Girard reagent.
- rac-l-hexadecyl-2-(5'- pentanoic methyl ester)-glycerol is hereby described.
- rac-l-Hexadecyl-2-(5'-pentanoic methyl ester)-glycerol is prepared in accordance with the teachings of the present invention, as is described in Schemes I through V below.
- l-Hexadecyl-3-tritylglycerol was prepared as described in U.S. Patent No. 6,838,452.
- the resulting solution was heated to 90 °C for 2 hours and was then cooled and poured on ice (150 grams). Then the mixture was extracted with dichloromethane (3 x 100 ml), the organic phase was washed with water (100 ml) and saturated aqueous solution of sodium dihydrogen phosphate and was dried over anhydrous Na 2 SO 4 . After removal of the solvent under reduced pressure 10.77 grams of crude product were obtained. The crude product was then dissolved in 80 % methanol (100 ml) and the solution was kept at 4 °C overnight. Filtration of the precipitate and removal of most of the solvent under reduced pressure.
- reaction mixture was cooled in ice-bath, alkaline solution (2.3 grams in 45 ml water) was added and the mixture was extracted with ether (3 x 25 ml).
- the etheral phase was washed with water and the water combined with the alkaline phase.
- the aqueous phase was acidified with concentrated HCl (4.4 ml) and extracted with ether (3 x 25 ml).
- the reaction mixture was then transferred to separatory funnel and extracted with dichloromethane (3 x 100 ml).
- the combined organic phase was washed with water (2 x 100 ml) and the solvent was removed under reduced pressure.
- the residue was dissolved in a mixture of methanol (80 ml) and 10 % aqueous NaOH (20 ml) and the solution was stirred at room temperature overnight.
- the methanolic solution was extracted with a mixture of toluene and hexane (1:1) (2 x 50 ml), cooled in ice-bath and HCl cone, was added slowly to reach pH 5-6.
- the solution was then extracted with dichloromethane (2 x 100 ml).
- an unsaturated moiety is introduced into a glycerolic backbone and is thereafter oxidized to an ester via an epoxide by means of acetic anhydride, 4-chlorobenzoperoxoic acid, HClO 4 periodate and methanol. Efficient isolation of the intermediates is performed by carrying out the reactions while using an acetate protecting group
- rac-l-hexadecyl-2-(5'- pentanoic methyl ester)-glycerol is hereby described.
- rac-l-Hexadecyl-2-(5'-pentanoic methyl ester )-glycerol is prepared in accordance with the teachings of the present invention, as is described in Schemes VI through X below.
- l-Hexadecyl-2-(5'-hexenyl)-3-tritylglycerol prepared as described in Example 1 above (4.90 grams) was dissolved in a mixture of methanol (30 ml) and concentrated hydrochloric acid (3 ml) and the resulting solution was heated to reflux for 4 hours. The reaction mixture was cooled to room temperature, poured on ice (100 grams) and extracted with chloroform (3 x 100 ml).
- l-Hexadecyl-3-tritylglycerol is prepared as described, for example, in
- a reactive phosphorous- containing moiety is introduced into a glycerolipid compound having one or two oxidized (or pre-oxidized) moiety-containing residues attached thereto via an ether bond.
- the introduction of the reactive phosphorous-containing moiety is performed using a phosphorous-containing compound such as, for example, phosphorous oxychloride).
- the reactive phosphorous-containing moiety is converted to a phosphate moiety.
- rac-l-hexadecyl-l- ⁇ S'-hexenytyS-dichlorophosphate As a representative example, rac-l-Hexadecyl-2-(5'-hexenyl)-3- dichlorophosphate was prepared in accordance with the teachings of the present invention, as is described in scheme XII below.
- the rac-l-Hexadecyl-2-(5'-hexenyl)-3-dichlorophosphate can be reacted with various alkylamine derivatives, to thereby produce a phosphoglyceride, as is exemplified below.
- the 1.2 gram off-white residue was dissolved in a mixture of 24 ml glacial acetic acid and 10 ml water, maintained at 70 °C for 1 hour and allowed to cool to room temperature.
- the product was extracted from the acetic acid solution by twice washing with 50 ml of a 2:1 chloroformrmethanol extraction solution. The solvents of the extraction solution were evaporated leaving 0.94 gram (1.7 mmol) rac-1- hexadecyl-2-(5'-hexenyl)-3-phosphoethanolamine, a yield of 85 % relative to the rac-
- reaction mixture was then cooled in an ice-bath and a solution of ethanolamine (0.16 ml) and triethylamine (0.64 ml) in THF (50 ml) was added dropwise thereto under vigorous stirring. The stirring was continued for additional 10 minutes in an ice-bath and further continued at room temperature for overnight. The reaction mixture was then filtered and the solvent removed under reduced pressure. The residue was dissolved in a mixture of acetic acid (24 ml) and water (10 ml) and the solution was heated to 70 °C for 1 hour. After cooling to room temperature, the mixture was extracted with chloroform (2 x 25ml) and the solvent was removed under reduced pressure.
- l-hexadecyl-2-(5'-hexenyl)-3-tritylglycerol is directly oxidized to obtain the corresponding carboxylic acid in a one-step procedure, thus circumventing the need to perform the oxidation via a multiple-step procedure that requires laborious separations of the intermediates.
- the oxidation step is performed using safe, efficient and less hazardous oxidizing agents. Purification procedures of all the intermediates are performed while avoiding the use of industrially inapplicable column chromatography.
- the reaction mixture was cooled to room temperature; water was added (100 ml) and the resulting mixture was extracted with dichloromethane (3 x 75 ml).
- the combined organic phase was washed with water (50 ml) and the solvent removed under reduced pressure.
- the residue was dissolved in 200 ml mixture of 90:10:5 methanol:water:concentrated hydrochloric acid (v/v) and the resulting solution was refluxed for 2 hours, followed by cooling to room temperature and addition of water (100 ml).
- the product was extracted with dichloromethane (3 x 100 ml), and the organic phase was washed consecutively with water (100 ml), saturated aqueous solution of sodium carbonate (100 ml) and again with water (100ml).
- l-Hexadecyl-2-(5'-hexenyl)-3 -tritylglycerol 50.00 grams, 78.0 mmol was dissolved in tert-butanol (500 ml) and the solution was added to the NaIO 4 ZKMnO 4 mixture during 1 hour. After 1.5 hours, analysis by TLC showed 80 % conversion. Additional amount of potassium permanganate (0.62 gram, 3.9 mmol, 0.05 equivalent) was added and the mixture was stirred for 1.5 hours. Analysis by TLC showed less than 5 % of the starting material. The reaction mixture was then cooled to room temperature and transferred to separation funnel.
- the intermediate l-Hexadecyl-2-(4'-carboxy)butyl-3-tritylglycerol was extracted with hexane (200 ml).
- the organic phase was washed with a solution of Na 2 S 2 O 5 (15 grams) in 100 ml water.
- Diluted hydrochloric acid (0.65 ml concentrated HCl in 13 ml water) was added to the organic phase and 200 ml of the solvent were distilled under reduced pressure. The remaining clear solution was heated to 80 °C for 6 hours. Analysis by TLC showed less than 5 % of intermediate l-Hexadecyl-2-(4'-ca ⁇ boxy)butyl-3-tritylglycerol. Additional volume of 250 ml solvent was distilled off.
- the precipitated triphenylmethanol was filter off and washed 4 times with 10 ml water.
- the filtrate was extracted with a mixture of 50 ml hexane and 50 ml ethyl acetate to remove remaining triphenylmethanol and other impurities.
- the sodium salt of l-hexadecyl-2-(4'-carboxy)butyl-sn-glycerol, present in the aqueous phase, was protonated with concentrated hydrochloric acid (8.45 ml, 101.4 mmol, 1.3 equivalents, pH l).
- l-Hexadecyl-2-(4 '-carboxymethyfybutyl-sn-glyceroS-phosphocholine A solution of l-Hexadecyl-2-(4'-carboxymethyl)butyl-glycerol (8.60 grams, 19.97 mmol), and triethylamine (2.63 grams, 3.62 ml, 26 mmol) in 500 ml THF was added dropwise, over 25 minutes, to an ice-cooled solution of POCl 3 (3.90 grams, 2.40 ml, 26 mmol) in 100 ml THF. The resulting mixture was stirred for an additional 10 minutes in an ice-bath and for 45 minutes at room temperature (23 °C).
- the crude l-hexadecyl-2-(4'-carboxymethyl)butyl-sn-glycero-3- phosphoethanolamine was dissolved in a mixture of isopropanol (500 ml) and dichloromethane (180 ml).
- a solution of potassium carbonate (50 grams) in water (100 ml) was added to reach a pH above 11, and the solution was kept at 35-40 0 C during the dropwise addition of methyltosylate (11.15 grams) in 100 ml of isopropanol in a time period of 45 minutes. After additional 90 minutes, the mixture was acidified with hydrochloric acid. Water (100 ml) and dichloromethane (550 ml) were added and the phases separated.
- the crude l-hexadecyl-2-(4'-carboxy)butyl-3-phosphocholine was purified by chromatography on a silica gel column. Dichloromethane followed by a mixture of dichloromethane, methanol, water, and triethylamine was used to elute the product from the column. The fractions containing the product were combined and evaporated. The resulting product was dried under vacuum. 7.10 grams of pure 1- hexadecyl-2-(4'-carboxy)butyl-3-phosphocholine (12.2 mmol, 66.1 % yield) were obtained. EXAMPLE 7
- the crude product was purified by chromatography on silica gel column (62 grams). The elution started with 200 ml CHCl 3 : MeOH 80 %:20 % to elute the non polar residues, then the polarity increased to 200 ml CHCl 3 :MeOH:Water 70 %:26 %:4 % and finally to 300 ml CHCl 3 :MeOH: Water 60 %:35 %:5 %. The product was eluted with the final mixture. The fractions were collected, the solvent was removed under reduced pressure, the residue was dissolved in chloroform and dried over anhydrous sodium sulfate and the solvent was removed reduced pressure. The product was dried under reduced pressure with phosphorus pentoxide. 1.0 gram of 1- hexadecyl-2-(6'-carboxy)hexanyl-sn-glycero-3-phosphocholine as white wax was obtained (58.1 % yield).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009545295A JP5453109B2 (en) | 2007-01-09 | 2008-01-02 | Improved process for the preparation of oxidized phospholipids |
CA2674902A CA2674902C (en) | 2007-01-09 | 2008-01-02 | Improved process for the preparation of oxidized phospholipids |
AU2008204238A AU2008204238B2 (en) | 2007-01-09 | 2008-01-02 | Improved process for the preparation of oxidized phospholipids |
KR1020097015780A KR20090109095A (en) | 2007-01-09 | 2008-01-02 | Improved process for the preparation of oxidized phospholipids |
ES08700247.3T ES2574586T3 (en) | 2007-01-09 | 2008-01-02 | Improved procedure for the preparation of oxidized phospholipids |
MX2009007422A MX2009007422A (en) | 2007-01-09 | 2008-01-02 | Improved process for the preparation of oxidized phospholipids. |
CN200880006707.6A CN101679463B (en) | 2007-01-09 | 2008-01-02 | Improved process for the preparation of oxidized phospholipids |
EP08700247.3A EP2125838B1 (en) | 2007-01-09 | 2008-01-02 | Improved process for the preparation of oxidized phospholipids |
NZ578947A NZ578947A (en) | 2007-01-09 | 2008-01-02 | Improved process for the preparation of oxidized phospholipids |
IL199792A IL199792A (en) | 2007-01-09 | 2009-07-09 | Process for the preparation of oxidized phospholipids |
HK10102729.2A HK1135990A1 (en) | 2007-01-09 | 2010-03-16 | Improved process for the preparation of oxidized phospholipids |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/650,973 | 2007-01-09 | ||
US11/650,973 US7807847B2 (en) | 2004-07-09 | 2007-01-09 | Process for the preparation of oxidized phospholipids |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008084472A2 true WO2008084472A2 (en) | 2008-07-17 |
WO2008084472A3 WO2008084472A3 (en) | 2009-11-26 |
Family
ID=39609128
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2008/000013 WO2008084472A2 (en) | 2007-01-09 | 2008-01-02 | Improved process for the preparation of oxidized phospholipids |
Country Status (14)
Country | Link |
---|---|
US (5) | US7807847B2 (en) |
EP (2) | EP2125838B1 (en) |
JP (2) | JP5453109B2 (en) |
KR (1) | KR20090109095A (en) |
CN (2) | CN101679463B (en) |
AU (1) | AU2008204238B2 (en) |
CA (2) | CA2674902C (en) |
ES (1) | ES2574586T3 (en) |
HK (1) | HK1135990A1 (en) |
IL (1) | IL199792A (en) |
MX (1) | MX2009007422A (en) |
NZ (3) | NZ593529A (en) |
WO (1) | WO2008084472A2 (en) |
ZA (1) | ZA200905601B (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010052718A1 (en) | 2008-11-06 | 2010-05-14 | Vascular Biogenics Ltd. | Oxidized lipid compounds and uses thereof |
US8124800B2 (en) | 2004-07-09 | 2012-02-28 | Vascular Biogenics Ltd. | Process for the preparation of oxidized phospholipids |
WO2013033642A1 (en) | 2011-09-01 | 2013-03-07 | Vascular Biogenics Ltd. | Formulations and dosage forms of oxidized phospholipids |
US8501715B2 (en) | 2003-05-27 | 2013-08-06 | Vascular Biogenics Ltd. | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders |
US8569529B2 (en) | 2007-01-09 | 2013-10-29 | Vascular Biogenics Ltd. | High-purity phospholipids |
US8999960B2 (en) | 2008-10-08 | 2015-04-07 | Vascular Biogenics Ltd. | Oxidized thiophospholipid compounds and uses thereof |
US9006217B2 (en) | 2007-01-09 | 2015-04-14 | Vascular Biogenics Ltd. | High-purity phospholipids |
US9771385B2 (en) | 2014-11-26 | 2017-09-26 | Vascular Biogenics Ltd. | Oxidized lipids |
US10022388B2 (en) | 2014-11-26 | 2018-07-17 | Vascular Biogenics Ltd. | Oxidized lipids and treatment or prevention of fibrosis |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7775245B2 (en) | 2005-04-08 | 2010-08-17 | Air Products And Chemicals, Inc. | Secure loop system and method for supply and delivery of product contained in a carrier |
JP2010047550A (en) * | 2008-08-25 | 2010-03-04 | Daicel Chem Ind Ltd | Method of preparing alkoxyalkane carboxylate |
CN104327114A (en) * | 2014-11-06 | 2015-02-04 | 江南大学 | Preparation method of phosphatidyl serine |
CN105622665B (en) * | 2016-03-16 | 2017-11-24 | 北京美亚斯磷脂技术有限公司 | A kind of preparation method of modified soy bean lipoid |
KR102208218B1 (en) * | 2016-06-30 | 2021-01-26 | 선전 와이에이치엘오 바이오텍 캄파니 리미티드 | Magnetic nanobead coated with modified cardiolipin and method for manufacturing the same |
CN110845357B (en) * | 2019-11-22 | 2022-09-30 | 华东理工大学 | Quaternary ammonium salt type hydrazide compound, quaternary ammonium salt type hydrazone compound prepared from same and application of quaternary ammonium salt type hydrazone compound |
US10953023B1 (en) | 2020-01-28 | 2021-03-23 | Applaud Medical, Inc. | Phospholipid compounds and formulations |
WO2021154220A1 (en) * | 2020-01-28 | 2021-08-05 | Applaud Medical, Inc. | Phospholipid compounds and formulations |
CN114195821B (en) * | 2021-12-17 | 2024-03-12 | 郑州安图生物工程股份有限公司 | Cardiolipin derivative and preparation method and application thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004106486A2 (en) | 2003-05-27 | 2004-12-09 | Vascular Biogenics Ltd. | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5638578B2 (en) * | 1973-05-18 | 1981-09-08 | ||
CH642665A5 (en) | 1979-02-08 | 1984-04-30 | Rudolf Berchtold | Process for the preparation of 1-(omega-carboxyalkyl)-2-alkyl- glycero-3-phosphatides |
US4329302A (en) * | 1980-06-27 | 1982-05-11 | Board Of Regents, The University Of Texas System | Synthetic phosphoglycerides possessing platelet activating properties |
DE3307925A1 (en) | 1983-03-05 | 1984-09-06 | A. Nattermann & Cie GmbH, 5000 Köln | NEW 0-ACYL-ALKANDIOL PHOSPHOLIPIDS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM |
US4614796A (en) * | 1983-03-25 | 1986-09-30 | Nippon Shinyaku Co., Ltd. | Liposome and method of manufacture therefor |
JPS6041652A (en) * | 1983-08-13 | 1985-03-05 | Morinaga Milk Ind Co Ltd | Preparation of n-carbobenzyloxy-l-glutamic acid-gamma- choline ester salt |
JPS60100544A (en) | 1983-11-08 | 1985-06-04 | Ono Pharmaceut Co Ltd | Novel glycerin derivative, its preparation and drug containing it |
JPS60104066A (en) | 1983-11-10 | 1985-06-08 | Ono Pharmaceut Co Ltd | Glycerin derivative, its preparation, and drug containing it |
AT383130B (en) | 1984-05-15 | 1987-05-25 | Chemie Linz Ag | METHOD FOR THE PRODUCTION OF PHOSPHATIDYLCHOLINES AND PHOSPHATIDYLETHANOLAMINES SUBSTITUTED DIFFERENTLY AT C1 AND C2 OVER THE NEW COMPOUNDS 1-0-TRITYLGLYCEROPHOSPHOCHOLIN OR RELATED (1-0, N-DITYHOHOLINE) |
JPH0617307B2 (en) | 1984-11-09 | 1994-03-09 | 武田薬品工業株式会社 | Antitumor agent |
US4710579A (en) | 1984-11-09 | 1987-12-01 | Takeda Chemical Industries, Ltd. | 2-(acetoacetyloxy)-3-(octadecyloxy)propyl-3-trimethylammoniopropyl phosphate or a pharmaceutically acceptable salt thereof |
US4827011A (en) * | 1984-12-10 | 1989-05-02 | American Cyanamid Company | Antihypertensive phosphate derivatives |
JPS61246196A (en) * | 1985-04-22 | 1986-11-01 | Fuji Kagaku Kogyo Kk | 5'-o-acyl-5-fluorouridine and production thereof |
EP0225129B1 (en) | 1985-11-29 | 1989-05-24 | Takeda Chemical Industries, Ltd. | Phospholipid derivatives, their production and use |
JPH01502584A (en) | 1986-03-24 | 1989-09-07 | ザ ユニバーシティー オブ シドニー | antigenic substance |
DE3777175D1 (en) * | 1986-04-07 | 1992-04-09 | Upjohn Co | ANTHELMINTIC QUATERNAERE ALKYL-ACYL-HYDRAZONE, METHOD FOR USE AND COMPOSITIONS. |
JPS6294A (en) | 1986-05-09 | 1987-01-06 | Toyama Chem Co Ltd | Novel glycerophosphoric acid derivative and salt and production thereof |
JPS6354386A (en) | 1986-08-26 | 1988-03-08 | Takeda Chem Ind Ltd | Phospholipid and use thereof |
JPS63190859A (en) * | 1986-09-18 | 1988-08-08 | Takeda Chem Ind Ltd | Glycerin derivative |
JPS63135395A (en) | 1986-11-28 | 1988-06-07 | Nippon Oil & Fats Co Ltd | Phospholipid derivative and production thereof |
JPS63188692A (en) * | 1987-01-29 | 1988-08-04 | Nippon Oil & Fats Co Ltd | Production of phospholipid derivative |
DE3807123A1 (en) | 1988-03-04 | 1989-09-14 | Boehringer Mannheim Gmbh | SUBSTRATE FOR PHOSPHOLIPASES |
JPH01258691A (en) | 1988-04-06 | 1989-10-16 | Nippon Oil & Fats Co Ltd | Phospholipid derivative and production thereof |
JP2534894B2 (en) | 1988-06-24 | 1996-09-18 | 日本ケミファ株式会社 | Novel glycerin derivative and antihypertensive agent containing the derivative |
JPH0248585A (en) | 1988-08-10 | 1990-02-19 | Nippon Oil & Fats Co Ltd | Phospholipid derivative and production thereof |
JPH03258740A (en) | 1990-03-06 | 1991-11-19 | Kao Corp | Liquid oil, production thereof and cosmetic containing same oil |
ES2019552A6 (en) | 1990-04-11 | 1991-06-16 | Menarini Lab | Process for the preparation of glycerophospholipids |
JP2869572B2 (en) | 1990-05-14 | 1999-03-10 | 和光純薬工業株式会社 | Method for producing phosphatidylcholine derivative |
US5561052A (en) * | 1992-06-18 | 1996-10-01 | Koike; Katsumasa | Process for detecting oxidized lipids and process for forming oxidized lipids |
FR2714382B1 (en) * | 1993-12-27 | 1996-02-02 | Roussel Uclaf | Phospholipids vector of active molecule, their preparation and their use in cosmetic or dermatological compositions. |
AU1751795A (en) | 1994-03-04 | 1995-09-18 | University Of British Columbia, The | Liposome compositions and methods for the treatment of atherosclerosis |
JP3364313B2 (en) | 1994-03-22 | 2003-01-08 | 株式会社トクヤマ | Porphyrin / indium complex and anion-sensitive membrane |
CA2197319C (en) | 1994-08-29 | 2009-01-27 | Louis S. Kucera | Lipid analogs for treating viral infections |
JPH08208548A (en) | 1995-02-01 | 1996-08-13 | Kao Corp | Production of glycerol derivative |
US5660855A (en) * | 1995-02-10 | 1997-08-26 | California Institute Of Technology | Lipid constructs for targeting to vascular smooth muscle tissue |
US6261597B1 (en) * | 1995-08-31 | 2001-07-17 | Seymour J. Kurtz | Method for treating periodontal disease |
US6096291A (en) * | 1996-12-27 | 2000-08-01 | Biovector Therapeutics, S.A. | Mucosal administration of substances to mammals |
HUP0002495A3 (en) * | 1997-07-31 | 2001-01-29 | American Home Prod | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by vla-4, pharmaceutical compositions comprising thereof and their use |
JP3781877B2 (en) | 1997-10-03 | 2006-05-31 | 株式会社ムック | Ascorbic acid derivatives or salts thereof, and pharmaceuticals |
US6376450B1 (en) | 1998-10-23 | 2002-04-23 | Chanchal Kumar Ghosh | Cleaning compositions containing multiply-substituted protease variants |
US6414168B1 (en) * | 1998-12-28 | 2002-07-02 | Caschem, Inc. | Epoxidation of ricinic compounds using a phase-transfer catalyst |
US6348583B1 (en) | 1999-08-30 | 2002-02-19 | Bio-Rad Laboratories, Inc. | Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids |
EP1233752B1 (en) | 1999-11-30 | 2005-01-26 | The Arizona Board of Regents on behalf of The University of Arizona | Radiation sensitive liposomes |
JP4675539B2 (en) | 2000-03-31 | 2011-04-27 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Functional assay for high density lipoprotein |
JP2002302470A (en) * | 2000-05-15 | 2002-10-18 | Toagosei Co Ltd | New quaternary ammonium salt and method for producing the same |
AU1846102A (en) * | 2000-11-24 | 2002-06-03 | Cardimmune Ltd | Methods employing and compositions containing defined oxidized phospholipids forprevention and treatment of atherosclerosis |
FI20011466A0 (en) * | 2001-07-04 | 2001-07-04 | Orion Corp | Compounds with activity that inhibit prolyl oligopeptidase, processes for their preparation and use thereof |
DE10155095A1 (en) | 2001-11-09 | 2003-05-22 | Cognis Deutschland Gmbh | ylglycerinethercarbonsäuren alkyl (s) |
US7807847B2 (en) * | 2004-07-09 | 2010-10-05 | Vascular Biogenics Ltd. | Process for the preparation of oxidized phospholipids |
WO2006006161A2 (en) * | 2004-07-09 | 2006-01-19 | Vascular Biogenics Ltd. | Improved process for the preparation of oxidized phospholipids |
US20060194765A1 (en) | 2004-11-16 | 2006-08-31 | Garcia Joe G N | Methods and compositions using oxidized phospholipids |
WO2007014001A2 (en) | 2005-07-21 | 2007-02-01 | The Board Of Trustees Of The Leland Stanford Junior University | Multiplex determination of lipid specific binding moieties |
US8137977B2 (en) | 2006-04-24 | 2012-03-20 | Children's Hospital & Research Center At Oakland | Lipidomic approaches to determining drug response phenotypes in cardiovascular disease |
US8703179B2 (en) | 2006-05-11 | 2014-04-22 | Kimberly-Clark Worldwide, Inc. | Mucosal formulation |
JP2008037763A (en) | 2006-08-01 | 2008-02-21 | Adeka Corp | Antibacterial agent and antibacterial agent composition |
US9006217B2 (en) | 2007-01-09 | 2015-04-14 | Vascular Biogenics Ltd. | High-purity phospholipids |
EA201070656A1 (en) | 2007-11-28 | 2010-12-30 | Тева Фармасьютикал Индастриз, Лтд. | METHOD OF DELAYING THE BEGINNING OF MANIFESTATION OF CLINICALLY DEFINED SCATTERED SCLEROSIS |
EP2348864A4 (en) | 2008-10-08 | 2013-07-31 | Vascular Biogenics Ltd | Oxidized thiophospholipid compounds and uses thereof |
EP2826369A3 (en) | 2008-11-06 | 2015-03-18 | Vascular Biogenics Ltd. | Oxidized lipid compounds and uses thereof |
JP2013516455A (en) | 2010-01-05 | 2013-05-13 | バスキュラー バイオジェニックス リミテッド | Treatment with VB-201 |
MX357759B (en) | 2011-09-01 | 2018-07-24 | Vascular Biogenics Ltd | Formulations and dosage forms of oxidized phospholipids. |
-
2007
- 2007-01-09 US US11/650,973 patent/US7807847B2/en active Active
-
2008
- 2008-01-02 CA CA2674902A patent/CA2674902C/en active Active
- 2008-01-02 NZ NZ593529A patent/NZ593529A/en not_active IP Right Cessation
- 2008-01-02 EP EP08700247.3A patent/EP2125838B1/en active Active
- 2008-01-02 ES ES08700247.3T patent/ES2574586T3/en active Active
- 2008-01-02 JP JP2009545295A patent/JP5453109B2/en active Active
- 2008-01-02 AU AU2008204238A patent/AU2008204238B2/en not_active Ceased
- 2008-01-02 CN CN200880006707.6A patent/CN101679463B/en not_active Expired - Fee Related
- 2008-01-02 KR KR1020097015780A patent/KR20090109095A/en active IP Right Grant
- 2008-01-02 CN CN201410145506.1A patent/CN103864842A/en active Pending
- 2008-01-02 NZ NZ578947A patent/NZ578947A/en not_active IP Right Cessation
- 2008-01-02 EP EP12178298A patent/EP2522672A1/en not_active Ceased
- 2008-01-02 NZ NZ603980A patent/NZ603980A/en not_active IP Right Cessation
- 2008-01-02 WO PCT/IL2008/000013 patent/WO2008084472A2/en active Application Filing
- 2008-01-02 MX MX2009007422A patent/MX2009007422A/en active IP Right Grant
- 2008-01-02 CA CA2844908A patent/CA2844908A1/en not_active Abandoned
-
2009
- 2009-07-09 IL IL199792A patent/IL199792A/en active IP Right Grant
- 2009-08-07 ZA ZA200905601A patent/ZA200905601B/en unknown
-
2010
- 2010-03-16 HK HK10102729.2A patent/HK1135990A1/en not_active IP Right Cessation
- 2010-08-24 US US12/861,921 patent/US8124800B2/en not_active Expired - Fee Related
-
2012
- 2012-01-26 US US13/358,573 patent/US20120130108A1/en not_active Abandoned
- 2012-12-10 US US13/709,198 patent/US8802875B2/en active Active
-
2013
- 2013-03-12 US US13/796,654 patent/US8759557B2/en active Active
-
2014
- 2014-01-06 JP JP2014000036A patent/JP2014088415A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6838452B2 (en) | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
WO2004106486A2 (en) | 2003-05-27 | 2004-12-09 | Vascular Biogenics Ltd. | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders |
Non-Patent Citations (1)
Title |
---|
See also references of EP2125838A4 |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8563534B2 (en) | 2000-11-24 | 2013-10-22 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
US8501715B2 (en) | 2003-05-27 | 2013-08-06 | Vascular Biogenics Ltd. | Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders |
US8124800B2 (en) | 2004-07-09 | 2012-02-28 | Vascular Biogenics Ltd. | Process for the preparation of oxidized phospholipids |
US8759557B2 (en) | 2004-07-09 | 2014-06-24 | Vascular Biogenics Ltd. | Process for the preparation of oxidized phospholipids |
US8802875B2 (en) | 2004-07-09 | 2014-08-12 | Vascular Biogenics Ltd. | Process for the preparation of oxidized phospholipids |
US9566288B2 (en) | 2007-01-09 | 2017-02-14 | Vascular Biogenics Ltd. | High-purity phospholipids |
US9006217B2 (en) | 2007-01-09 | 2015-04-14 | Vascular Biogenics Ltd. | High-purity phospholipids |
US8569529B2 (en) | 2007-01-09 | 2013-10-29 | Vascular Biogenics Ltd. | High-purity phospholipids |
US8999960B2 (en) | 2008-10-08 | 2015-04-07 | Vascular Biogenics Ltd. | Oxidized thiophospholipid compounds and uses thereof |
EP2826369A2 (en) | 2008-11-06 | 2015-01-21 | Vascular Biogenics Ltd. | Oxidized lipid compounds and uses thereof |
WO2010052718A1 (en) | 2008-11-06 | 2010-05-14 | Vascular Biogenics Ltd. | Oxidized lipid compounds and uses thereof |
EP2826370A2 (en) | 2008-11-06 | 2015-01-21 | Vascular Biogenics Ltd. | Oxidized lipid compounds and uses thereof |
JP2015129157A (en) * | 2008-11-06 | 2015-07-16 | ヴァスキュラー バイオジェニックス リミテッド | Oxidized lipid compound and use thereof |
US9206206B2 (en) | 2008-11-06 | 2015-12-08 | Vascular Biogenics Ltd. | Oxidized lipid compounds and uses thereof |
JP2012507577A (en) * | 2008-11-06 | 2012-03-29 | ヴァスキュラー バイオジェニックス リミテッド | Oxidized lipid compounds and uses thereof |
WO2013033642A1 (en) | 2011-09-01 | 2013-03-07 | Vascular Biogenics Ltd. | Formulations and dosage forms of oxidized phospholipids |
US9254297B2 (en) | 2011-09-01 | 2016-02-09 | Vascular Biogenics Ltd. | Formulations and dosage forms of oxidized phospholipids |
US9771385B2 (en) | 2014-11-26 | 2017-09-26 | Vascular Biogenics Ltd. | Oxidized lipids |
US10022388B2 (en) | 2014-11-26 | 2018-07-17 | Vascular Biogenics Ltd. | Oxidized lipids and treatment or prevention of fibrosis |
US10206936B2 (en) | 2014-11-26 | 2019-02-19 | Vascular Biogenics Ltd. | Oxidized lipids and treatment or prevention of fibrosis |
US10464957B2 (en) | 2014-11-26 | 2019-11-05 | Vascular Biogenics Ltd. | Oxidized lipids and methods of use thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8124800B2 (en) | Process for the preparation of oxidized phospholipids | |
EP2604614B1 (en) | Oxidized phospholipids | |
US9968622B2 (en) | High-purity phospholipids | |
US8569529B2 (en) | High-purity phospholipids | |
AU2007200090B2 (en) | Improved Process for the Preparation of Oxidized Phospholipids | |
IL211795A (en) | Process for the preparation of oxidized phospholipids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880006707.6 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08700247 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2674902 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2009545295 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2009/007422 Country of ref document: MX Ref document number: 199792 Country of ref document: IL |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097015780 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008204238 Country of ref document: AU Ref document number: 4655/CHENP/2009 Country of ref document: IN Ref document number: 2008700247 Country of ref document: EP Ref document number: 578947 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2008204238 Country of ref document: AU Date of ref document: 20080102 Kind code of ref document: A |